Clinical Cancer Research, Vol 3, Issue 9 1473-1477, Copyright © 1997 by American Association for Cancer Research

ARTICLES

Frequent loss of p16 expression and its correlation with clinicopathological parameters in pancreatic carcinoma

YX Hu, H Watanabe, K Ohtsubo, Y Yamaguchi, A Ha, T Okai and N Sawabu
Department of Internal Medicine, Cancer Research Institute, Kanazawa University, 4-86 Yoneizumi, Kanazawa 921, Japan.

Expression of the p16 gene product in human primary pancreatic carcinoma (PC) was investigated in paraffin-embedded tissue using a monoclonal antibody against p16 protein, clone G175-405, by means of immunohistochemistry, and the correlation of results with various clinicopathological parameters was evaluated. All six cases of normal pancreas and all but 1 of 20 cases of chronic pancreatitis expressed p16 protein, whereas 37.5% (3 of 8) of cystadenomas and 41. 9% (26 of 62) of PCs lost p16 expression. There was a significant difference between chronic pancreatitis and PC for frequency of the loss of p16 expression (P < 0.01). Moreover, loss of p16 expression in pancreatic malignancy was significantly associated with histological grade (G1 versus G2 and G3, P < 0.01) but not with sex, age, clinical stage, tumor location, or resectability. The survival period was shorter and metastasis is more likely in those cases that did not show p16 expression than those that did.

This article has been cited by other articles:

				M. Abdelrahim, R. Smith III, R. Burghardt, and S. Safe Role of Sp Proteins in Regulation of Vascular Endothelial Growth Factor Expression and Proliferation of Pancreatic Cancer Cells Cancer Res., September 15, 2004; 64(18): 6740 - 6749. [Abstract] [Full Text] [PDF]

				A V Biankin, S A Biankin, J G Kench, A L Morey, C-S Lee, D R Head, R P Eckstein, T B Hugh, S M Henshall, and R L Sutherland Aberrant p16INK4A and DPC4/Smad4 expression in intraductal papillary mucinous tumours of the pancreas is associated with invasive ductal adenocarcinoma Gut, June 1, 2002; 50(6): 861 - 868. [Abstract] [Full Text] [PDF]

				H. Han, D. J. Bearss, L. W. Browne, R. Calaluce, R. B. Nagle, and D. D. Von Hoff Identification of Differentially Expressed Genes in Pancreatic Cancer Cells Using cDNA Microarray Cancer Res., May 1, 2002; 62(10): 2890 - 2896. [Abstract] [Full Text] [PDF]

				C. Gessner, U. Liebers, H. Kuhn, P. Stiehl, C. Witt, J. Schauer, and G. Wolff BAX and p16INK4A are independent positive prognostic markers for advanced tumour stage of nonsmall cell lung cancer Eur. Respir. J., January 1, 2002; 19(1): 134 - 140. [Abstract] [Full Text] [PDF]

				K. M. Anderson and J. E. Harris Selected Features of Nonendocrine Pancreatic Cancer Experimental Biology and Medicine, June 1, 2001; 226(6): 521 - 537. [Abstract] [Full Text] [PDF]

				I. Sturm, H. Petrowsky, R. Volz, M. Lorenz, S. Radetzki, T. Hillebrand, G. Wolff, S. Hauptmann, B. Dorken, and P. T. Daniel Analysis of p53/BAX/p16ink4a/CDKN2 in Esophageal Squamous Cell Carcinoma: High BAX and p16ink4a/CDKN2 Identifies Patients With Good Prognosis J. Clin. Oncol., April 15, 2001; 19(8): 2272 - 2281. [Abstract] [Full Text] [PDF]

				S.-B. Su, Y. Motoo, J. L. Iovanna, M.-J. Xie, H. Mouri, K. Ohtsubo, Y. Yamaguchi, H. Watanabe, T. Okai, F. Matsubara, et al. Expression of p8 in Human Pancreatic Cancer Clin. Cancer Res., February 1, 2001; 7(2): 309 - 313. [Abstract] [Full Text]

				R. Hui, R. D. Macmillan, F. S. Kenny, E. A. Musgrove, R. W. Blamey, R. I. Nicholson, J. F. R. Robertson, and R. L. Sutherland INK4a Gene Expression and Methylation in Primary Breast Cancer: Overexpression of p16INK4a Messenger RNA Is a Marker of Poor Prognosis Clin. Cancer Res., July 1, 2000; 6(7): 2777 - 2787. [Abstract] [Full Text]

				O. Straume, L. Sviland, and L. A. Akslen Loss of Nuclear p16 Protein Expression Correlates with Increased Tumor Cell Proliferation (Ki-67) and Poor Prognosis in Patients with Vertical Growth Phase Melanoma Clin. Cancer Res., May 1, 2000; 6(5): 1845 - 1853. [Abstract] [Full Text]